|
☑ Filed by the Registrant
|
| |
☐ Filed by a Party other than the Registrant
|
|
| | Check the appropriate box: | | | ||||
| | ☑ | | | |
Preliminary Proxy Statement
|
| |
| |
☐
|
| | |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
| |
| | ☐ | | | |
Definitive Proxy Statement
|
| |
| | ☐ | | | |
Definitive Additional Materials
|
| |
| |
☐
|
| | | Soliciting Material under §240.14a-12 | | |
| | Payment of Filing Fee (Check the appropriate box): | | | ||||
| |
☑
|
| | |
No fee required.
|
| |
| |
☐
|
| | |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
| |
|
(1)
Title of each class of securities to which transaction applies:
(2)
Aggregate number of securities to which transaction applies:
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
Proposed maximum aggregate value of transaction:
(5)
Total fee paid:
|
| | |||||
| |
☐
|
| | |
Fee paid previously with preliminary materials.
|
| |
| |
☐
|
| | |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
| |
|
(1)
Amount Previously Paid:
(2)
Form, Schedule or Registration Statement No.:
(3)
Filing Party:
(4)
Date Filed:
|
| |
|
|
| |
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
ii
|
|
|
iii
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
iv
|
|
Table |
|
| | | | | 3 | | | |
| | | | | 6 | | | |
| Resolutions and Voting | | | |
|
| | |
| Proposal No. 1 Election of Directors | | | |
|
8 | | |
| Corporate Governance | | | |
|
9 | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 15 | | | |
| | | | | 16 | | | |
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| Executive Compensation | | | |
|
25 | | |
| | | | | 25 | | | |
| | | | | 38 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 33 | | | |
| | | | | 35 | | |
|
1
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
2
|
|
|
|
| |
Internet
www.envisionreports.com/LIVN or as directed by your broker, as the case may be |
|
|
|
| |
Telephone
Call the number on your proxy card |
|
|
|
| |
By mail
Sign, date and return your proxy card in the enclosed envelope |
|
|
|
| |
At the meeting: Attend virtually at www.meetingcenter.io/260382039 (Password: LIVN2020)
|
|
|
3
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Proposal
|
| |
Board
Recommendation |
| |
For More
Information |
|
| | | | | Page 8 | | ||
| | | “FOR” | | | Page 50 | | |
| | | “FOR” | | | Page 54 | | |
| Proposal 4 – To grant authority to allot shares for a period of five years | | | “FOR” | | | Page 55 | |
| | | “FOR” | | | Page 57 | | |
| Proposal 6 – Special Resolution to adopt the New Articles | | | “FOR” | | | Page 58 | |
| | | “FOR” | | | Page 62 | | |
| | | “FOR” | | | Page 63 | | |
| | | “FOR” | | | Page 64 | | |
| | | “FOR” | | | Page 65 | |
|
Name
|
| |
Age
|
| |
Director
Since |
| |
Principal Position
|
| |
Independent
|
| |||||||||
| Francesco Bianchi | | | | | 63 | | | | | | 2015 | | | | Chairman, Seven Capital Partners S.r.l. | | | | | Yes | | |
| Stacy Enxing Seng | | | | | 55 | | | | | | 2019 | | | | Venture Partner, Lightstone Ventures | | | | | Yes | | |
| William Kozy | | | | | 68 | | | | | | 2018 | | | | Retired, EVP and COO, Becton, Dickinson and Company | | | | | Yes | | |
| Damien McDonald | | | | | 55 | | | | | | 2017 | | | | CEO, LivaNova | | | | | No | | |
| Daniel Moore | | | | | 59 | | | | | | 2015 | | | | Chairman of the Board; private investor | | | | | Yes | | |
| Hugh Morrison | | | | | 73 | | | | | | 2015 | | | | Independent consultant and private investor | | | | | Yes | | |
| Alfred Novak | | | | | 72 | | | | | | 2015 | | | | Private investor | | | | | Yes | | |
| Sharon O’Kane, Ph.D. | | | | | 52 | | | | | | 2015 | | | | Entrepreneur in Residence, University College Dublin | | | | | Yes | | |
| Arthur Rosenthal, Ph.D. | | | | | 73 | | | | | | 2015 | | | | Retired CEO, EyeCue, Inc | | | | | Yes | | |
| Andrea Saia | | | | | 62 | | | | | | 2016 | | | |
Retired, Global Head of Vision Care, Alcon Division, Novartis AG
|
| | | | Yes | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
4
|
|
|
5
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
6
|
|
|
7
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| Francesco Bianchi | | | Hugh Morrison | |
| Stacy Enxing Seng | | | Alfred Novak | |
| William Kozy | | | Sharon O’Kane, Ph.D. | |
| Damien McDonald | | | Arthur Rosenthal, Ph.D. | |
| Daniel Moore | | | Andrea Saia | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
8
|
|
| Corporate Governance | |
| The Board of Directors | |
|
9
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
The Board of Directors
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
10
|
|
| Corporate Governance | |
| The Board of Directors | |
|
FRANCESCO BIANCHI
|
| ||||||
|
INDEPENDENT
Age 63
Director
since 2015
Chairman
Seven Capital Partners S.r.l. |
| |
Francesco Bianchi has served as the Chairman of Seven Capital Partners S.r.l., a financial consulting firm, since June 2018, previously served as Seven Capital Partners Chief Executive Officer and has been with the firm since 2013. Mr. Bianchi has 30 years of mergers and acquisitions and strategic advisory experience working for well-recognized international financial institutions including JPMorgan Chase (Paris), Morgan Grenfell (London), Citi (Milan) and Bankers Trust (Milan), where he served in various roles including general manager and head of the mergers and acquisitions and corporate finance division. He also headed the strategic planning division of Banca-Intesa S.p.A. in Italy and abroad. Mr. Bianchi earned a degree in economic sciences with honors from the University of Florence and is a chartered accountant.
|
| |||
|
Committees:
•
Audit and Compliance; Compensation
Other Public Company Directorships:
•
None
|
| |
Former Public Company Directorships During the Past Five Years:
•
Sorin S.p.A.;
•
Intesa Sanpaulo S.p.A.
Director Skills and Qualifications:
•
Mr. Bianchi is an audit committee financial expert and has an extensive professional background working in strategy and mergers and acquisitions.
|
|
|
STACY ENXING SENG
|
| ||||||
|
INDEPENDENT
Age 55
Director
since 2019
Venture Partner
Lightstone Ventures |
| |
Stacy Enxing Seng has served as a Venture Partner with Lightstone Ventures, a venture capital group focused on medical technology and biotechnology-related investments, since 2016. Prior to joining Lightstone, Ms. Enxing Seng was with Covidien, a global health care products company, as its President, Vascular Therapies (2011 to 2014) and President of Peripheral Vascular (2010 to 2011). Ms. Enxing Seng joined Covidien in 2010 through the $2.6B acquisition of ev3 Incorporated, where she was a founding member and executive officer responsible for leading its Peripheral Vascular division (2001 to 2010). Prior to ev3, Ms. Enxing Seng held positions of increasing responsibility with Boston Scientific, SCIMED, Baxter and American Hospital Supply. She holds a B.A. in Public Policy from Michigan State University and an M.B.A. from Harvard University.
|
| |||
|
Committees:
•
Compensation
Other Public Company Directorships:
•
Sonova Holding AG; Hill-Rom Holdings, Inc.
|
| |
Director Skills and Qualifications:
•
Ms. Enxing Seng has broad experience as a former senior executive responsible for a world-wide business unit of a major medical device company. In addition, she has significant experience as a co-founder of a successful medical device start-up. Her operational experience at both large and small medical device companies, combined with her first-hand experience gained from building ev3 from the ground up, provide the Board with valuable insights into strategy, marketing, sales, innovation, mergers and acquisitions and a variety of other medical device-related areas.
|
|
|
11
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
The Board of Directors
|
|
|
William Kozy
|
| ||||||
|
Independent
Age 68
Director
since 2018
Retired, EVP and COO Becton, Dickinson and Company
|
| |
William Kozy retired from Becton, Dickinson and Company, a global medical technology company, in 2016 where he was Executive Vice President and Chief Operating Officer from 2011 to 2016. At Becton Dickinson, he also served as a member of the corporate Leadership Team and in various executive roles since 1988, including head of BD Medical (2009 to 2011), President of the BD Biosciences segment (2006 to 2009), President of BD Diagnostics (2002 to 2006) and Senior Vice President of Company Operations (1998 to 2002). Mr. Kozy graduated cum laude from Kenyon College.
|
| |||
|
Committees:
•
Nominating and Corporate Governance
|
| |
Other Public Company Directorships:
•
Cooper Companies, Inc.
Director Skills and Qualifications:
•
Mr. Kozy has a career spanning more than 40 years with global medical device companies. Prior to serving as COO for Becton Dickinson, Mr. Kozy’s key business worldwide leadership roles included responsibility for the Biosciences, Diagnostic and Medical segments of Becton Dickinson. During his time at Becton Dickinson, he was responsible for all world-wide businesses of the company with leadership emphasis on profitable revenue growth and talent development. He also brings a depth of corporate leadership experience in the areas of innovation systems, operations, manufacturing and ERP implementation as well as his broad and relevant experience in global strategy, mergers and acquisitions, technology and product development.
|
|
|
Damien McDonald
|
| ||||||
|
Age 55
Director
since 2017
CEO
LivaNova |
| |
Damien McDonald has served as the CEO and an executive director of the Company since January 2017 and served as the Company’s Chief Operating Officer from October through December 2016. Prior to joining the Company, Mr. McDonald was with Danaher Corporation, a global manufacturer of medical, industrial and commercial products, where he was Group President, Professional Consumables (2013 to 2016). From 2011 to 2013, Mr. McDonald served as Group President of Kerr Corporation, a subsidiary of Danaher, where he was responsible for a dental consumable business with operations in the US, Mexico, Switzerland, Italy and the Czech Republic. In 2010, Mr. McDonald undertook special projects for Danaher. From 2007 to 2010, Mr. McDonald was president, Zimmer Spine at Zimmer Holdings, where he was responsible for divisions in the US and France. From 1999 to 2007, Mr. McDonald had various roles with Johnson and Johnson. Mr. McDonald holds bachelor’s degrees in pharmacy and economics from the University of Queensland in Australia, a master’s degree in international economics from the University of Wales, and an M.B.A. from the Institute for Management Development in Lausanne.
|
| |||
|
Committees:
•
None
|
| |
Other Public Company Directorships:
•
Avita Medical Limited
Director Skills and Qualifications:
•
Mr. McDonald has extensive management experience in the medical device and life sciences industries and serves as the CEO of the Company.
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
12
|
|
| Corporate Governance | |
| The Board of Directors | |
|
Daniel Moore
|
| ||||||
|
Independent
Age 59
Director
since 2015
Chairman of the Board and private investor
|
| |
Daniel Moore is Chairman of the Board of the Company and, over the past five years, has served primarily as a private investor. Mr. Moore served as President and CEO and a member of the board of Cyberonics, Inc., a medical device company with core expertise in neuromodulation, from 2007 to 2015 when Cyberonics merged with Sorin S.p.a. to form the Company. Mr. Moore joined Cyberonics after 18 years with Boston Scientific where he was President of InterContinental as well as having roles in general management, sales and marketing earlier in his career. Mr. Moore has a B.A. from Harvard College and an Executive M.B.A. from Boston University.
|
| |||
|
Committees:
•
None as Chairman of the Board
Other Public Company Directorships:
•
GI Dynamics, Inc.; ViewRay, Inc.
|
| |
Former Public Company Directorships During the Past Five Years:
•
Cyberonics, Inc.
Director Skills and Qualifications:
•
Mr. Moore has extensive experience working with cutting edge medical device companies, including leadership of Cyberonics. He has significant experience in domestic and international general management and sales and marketing. Mr. Moore serves or has served on the boards of several medical device companies, the Epilepsy Foundation of America and other non-profits focused on epilepsy, the Medical Device Manufacturers Association and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering. His board service includes many board chairman roles.
|
|
|
Hugh Morrison
|
| ||||||
|
Independent
Age 73
Director
since 2015
Independent consultant and private investor
|
| |
Hugh Morrison has worked as an independent consultant and private investor since 2012. From 2008 to 2012, Mr. Morrison was a Managing Director at Callahan Advisors, LLC, an investment management company. From 1996 to 2006, he served as President and Chief Executive Officer of Pilgrim Cleaners, Inc., a retail dry cleaning company operating over 100 stores. Mr. Morrison has a BBA in Accounting from Texas A&M University-Kingsville and is a licensed CPA.
|
| |||
|
Committees:
•
Audit and Compliance (Chair); Nominating and Corporate Governance
Other Public Company Directorships:
•
None
|
| |
Former Public Company Directorships During the Past Five Years:
•
Cyberonics, Inc.
Director Skills and Qualifications:
•
Mr. Morrison has extensive board leadership experience in the healthcare sector having served as chairman of the board of Advanced Neuromodulation Systems, Inc. where he gained specific knowledge of neurostimulation device technology and products, and on the boards of Owen Healthcare, Inc. and Dow Hickam Pharmaceuticals, Inc. Mr. Morrison is also an audit committee financial expert.
|
|
|
13
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
The Board of Directors
|
|
|
Alfred Novak
|
| ||||||
|
Independent
Age 72
Director
since 2015
Private investor
|
| |
Alfred Novak has worked as a private investor since 2015. Prior to that, Mr. Novak served as President and CEO of Syntheon Cardiology LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve (2014 to 2015); Chairman and CEO of OrbusNeich Medical Technology Company, Ltd., an interventional cardiology company (2010 to 2013); President and CEO of Novoste Corporation, an interventional cardiology company (2002 to 2006); founder of Syntheon, LLC, a company focused on minimally invasive medical devices for the gastroenterology and vascular markets (1998 to 2003); and President, CEO and a director of Biosense, Inc., an electrophysiology company (1996 to 1998). Prior to that time, Mr. Novak was Vice President and Chief Financial Officer of Cordis Corporation. Mr. Novak received a BS from the United States Merchant Marine Academy and an M.B.A. in Healthcare from The Wharton School of the University of Pennsylvania.
|
| |||
|
Committees:
•
Audit and Compliance; Compensation
Other Public Company Directorships:
•
None
|
| |
Former Public Company Directorships During the Past Five Years:
•
Cyberonics, Inc., Dova Pharmaceuticals, Inc.
Director Skills and Qualifications:
•
Mr. Novak has broad operating executive experience as CEO and CFO as well as leading marketing and sales at medical device companies. In addition, he has board of director experience at medical device and pharmaceutical companies, including service on audit and compensation committees. Further, he has expertise concerning new product development, regulatory approval and commercialization of medical devices. Mr. Novak is also an audit committee financial expert.
|
|
|
Sharon O’Kane
|
| ||||||
|
Independent
Age 52
Director
since 2015
Entrepreneur in Residence
University College Dublin |
| |
Sharon O’Kane, Ph.D., has served as an Entrepreneur in Residence at University College Dublin since 2015. She was also an expert advisor to the Stevenage Bioscience Catalyst Facility at GlaxoSmithKline, a global healthcare company (2012 to 2019) and a Commercial Mentor to Queen’s University, Belfast (2016 to 2019). Previously, Dr. O’Kane served as Entrepreneur in Residence at the University of Manchester Intellectual Property Company UMIP (2009 to 2014). Dr O’Kane co-founded and, from 1998 to 2010, was the Chief Scientific Officer, and a Director of Renovo Group Plc, a UK biotech company. Dr. O’Kane earned a B.Sc (Honours) First Class in Biomedical Sciences from the University of Ulster from which she also earned a Ph.D. in Biomedical Sciences. She also earned a Diploma in Company Direction from the Institute of Directors.
|
| |||
|
Committees:
•
Nominating and Corporate Governance (Chair)
Other Public Company Directorships:
•
None
|
| |
Director Skills and Qualifications:
•
Dr. O’Kane has extensive experience in healthcare, both in the academic realm and in research and development (R&D) capacities. She has served on the board of directors of several biotech and healthcare companies and organizations and has held numerous positions advising healthcare and biotech companies, governmental bodies and universities. Dr. O’Kane was also a co-founder, Chief Science Officer and executive director of Renovo Group Plc and was responsible for growing the university spin-out to a public company, and a non-executive director of Iomet Pharma Ltd. Dr. O’Kane has had corporate director governance training at the Institute of Directors and Harvard Business School.
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
14
|
|
| Corporate Governance | |
| The Board of Directors | |
|
Arthur Rosenthal
|
| ||||||
|
Independent
Age 73
Director
since 2015
Retired CEO
EyeCue, Inc. |
| |
Arthur Rosenthal, PhD retired from EyeCue, Inc., a development-stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening, after serving as co-founder and CEO from 2011 to 2015. Dr. Rosenthal also served as Professor of Practice in the Biomedical Engineering Department at Boston University from 2010 to 2015. Prior to co-founding EyeCue in 2011, Dr. Rosenthal served as President and CEO of Cappella, Inc., a development-stage company focused on novel device solutions for coronary artery disease (2009 to 2011); CEO of Labcoat, Ltd., a development-stage drug-eluting stent technology company, from 2005 until its acquisition by Boston Scientific Corporation in 2008; Senior Vice President, Chief Science Officer and Executive Committee Member of Boston Scientific, a medical device manufacturer (2000 to 2005); and Senior Vice President, Corporate Officer and Chief Development Officer at Boston Scientific (1994 to 2000). Dr. Rosenthal earned his Bachelor Degree in Bacteriology from the University of Connecticut and a Ph.D in Biochemistry from the University of Massachusetts.
|
| |||
|
Committees:
•
Compensation (Chair)
Other Public Company Directorships:
•
Profound Medical Corp.
|
| |
Former Public Company Directorships During the Past Five Years:
•
Cyberonics, Inc.; Arch Therapeutics, Inc.
Director Skills and Qualifications:
•
For more than 40 years, Dr. Rosenthal has developed medical device technologies as an individual contributor, technology executive and serial entrepreneur. He has extensive knowledge of regulatory and compliance requirements pertaining to medical devices and experience with new product development and technology commercialization as well as having served as an operating executive with a major medical device manufacturer.
|
|
|
Andrea Saia
|
| ||||||
|
Independent
Age 62
Director
since 2016
Retired, Global Head of Vision Care
Alcon Division, Novartis AG |
| |
Andrea Saia served as the Global Head of Vision Care in the Alcon Division of Novartis AG, a global healthcare company, from 2011 until her retirement in 2012. Prior to this role, she served as President and CEO of CibaVision Corporation, a subsidiary of Novartis, from 2008 to 2011. From 2005 to 2007, Ms. Saia relocated to Switzerland and served as President of Europe, Middle East and Africa operations, CibaVision’s largest regional business unit. She joined CibaVision in 2002 as Global Head of Marketing and was promoted to President of the Global Lens Business in 2003. Prior to joining Novartis, Ms. Saia was the Chief Marketing Officer for GCG Partners and also held senior management and marketing positions with global consumer products companies such as Procter & Gamble Co., Unilever and Revlon, Inc. Ms. Saia earned her B.S. in Business Administration from Miami University and her M.B.A. from J.L. Kellogg Graduate School of Management.
|
| |||
|
Committees:
•
Audit and Compliance
Other Public Company Directorships:
•
Align Technology
|
| |
Former Public Company Directorships During the Past Five Years:
•
Coca Cola Enterprises
Director Skills and Qualifications:
•
Ms. Saia is an accomplished global business executive with nearly 40 years’ experience in the medical device and consumer products industries including multinational companies such as Novartis, Unilever, Revlon and Procter & Gamble, and continuing involvement in business matters as a member of the Miami University Farmer School of Business Advisory Board. She has extensive global business experience, a broad understanding of healthcare, medical device and consumer products industries, strong management skills and significant operations experience.
|
|
|
15
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
The Board of Directors
|
|
| Francesco Bianchi | | | Alfred Novak | |
| Stacy Enxing Seng | | | Sharon O’Kane | |
| William Kozy | | | Arthur Rosenthal | |
| Daniel Moore | | | Andrea Saia | |
| Hugh Morrison | | | | |
|
Directors
|
| |
Nasdaq
“Independent Director” |
| |
Nasdaq
Independence for Compensation Committee Purposes |
| |
“Non-Employee
Director” |
| |
Audit Committee
Financial Expert |
|
|
Francesco Bianchi
|
| |
✔
|
| |
✔
|
| |
✔
|
| |
✔
|
|
|
Stacy Enxing Seng
|
| |
✔
|
| |
✔
|
| |
✔
|
| | | |
|
William Kozy
|
| |
✔
|
| |
✔
|
| |
✔
|
| | | |
|
Damien McDonald
|
| | | | | | | | | | | | |
|
Daniel Moore
|
| |
✔
|
| |
✔
|
| |
✔
|
| | | |
|
Hugh Morrison
|
| |
✔
|
| |
✔
|
| |
✔
|
| |
✔
|
|
|
Alfred Novak
|
| |
✔
|
| |
✔
|
| |
✔
|
| |
✔
|
|
|
Sharon O’Kane
|
| |
✔
|
| |
✔
|
| |
✔
|
| | | |
|
Arthur Rosenthal
|
| |
✔
|
| |
✔
|
| |
✔
|
| | | |
|
Andrea Saia
|
| |
✔
|
| |
✔
|
| |
✔
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
16
|
|
| Corporate Governance | |
| The Board of Directors | |
|
17
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
Board, Committee and Shareholder Meetings
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
18
|
|
| Corporate Governance | |
| Board, Committee and Shareholder Meetings | |
| | | |
Members of the Board’s standing committees as of
December 31, 2019 |
| ||||||
| | | |
Compensation
Committee |
| |
Nominating and
Corporate Governance Committee |
| |
Audit and Compliance
Committee |
|
|
Francesco Bianchi
|
| |
✔
|
| | | | |
✔
|
|
|
Stacy Enxing Seng
|
| |
✔
|
| | | | | | |
|
William Kozy
|
| | | | |
✔
|
| | | |
| Damien McDonald | | | | | | | | | | |
|
Daniel Moore
(Chairman of the Board)
|
| | | | | | | | | |
|
Hugh Morrison
|
| | | | |
✔
|
| |
✔
|
|
|
Alfred Novak
|
| |
✔
|
| | | | |
✔
|
|
|
Sharon O’Kane
|
| | | | |
✔
|
| | | |
|
Arthur Rosenthal
|
| |
✔
|
| | | | | | |
|
Andrea Saia
|
| | | | | | | |
✔
|
|
| | | |
Committee Actions in 2019
|
| ||||||
| Meetings | | |
10
|
| |
4
|
| |
10
|
|
| Written Resolutions | | |
2
|
| |
–
|
| |
1
|
|
|
19
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
Board, Committee and Shareholder Meetings
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
20
|
|
| Corporate Governance | |
| Board, Committee and Shareholder Meetings | |
|
21
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
Board, Committee and Shareholder Meetings
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
22
|
|
| Corporate Governance | |
| Executive Officers | |
|
Name
|
| |
Age
|
| |
Position
|
|
| Damien McDonald | | |
55
|
| | Chief Executive Officer | |
| Thad Huston | | |
50
|
| | Chief Financial Officer | |
| Keyna Skeffington | | |
58
|
| | Senior Vice President, General Counsel and Company Secretary | |
| Edward Andrle | | |
62
|
| | Former General Manager, Neuromodulation Franchise | |
| Alistair Simpson | | |
50
|
| | Former General Manager, Cardiovascular Franchise | |
| Marco Dolci | | |
58
|
| | Head of Global Operations and R&D | |
| Trui Hebbelinck | | |
48
|
| | Chief Human Resources Officer | |
| Roy Khoury | | |
46
|
| | President, International, Senior Vice President, Global Strategic Marketing | |
|
23
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Corporate Governance
|
|
|
Executive Officers
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
24
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
|
25
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
26
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
|
27
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
| Abiomed, Inc. | | | Masimo Corporation | |
| Cantel Medical Corp. | | | Merit Medical Systems, Inc. | |
| CONMED Corporation | | | Nuvasive, Inc. | |
| DexCom, Inc. | | | ResMed Inc. | |
| Globus Medical, Inc. | | | STERIS plc | |
| Hill-Rom Holdings, Inc. | | | Teleflex Incorporated | |
| Hologic, Inc. | | | The Cooper Companies, Inc. | |
| ICU Medical, Inc. | | | Varian Medical Systems, Inc. | |
| Integer Holdings, Corporation | | | West Pharmaceutical Services, Inc. | |
| Integra LifeSciences Holdings Corporation | | | Wright Medical Group, N.V. | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
28
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
|
Element and Purpose
|
| |
Key Features
|
|
|
Base Salary
Purpose: Attract and retain NEOs; compensate for individual performance |
| |
Fixed annually at the beginning of the financial year by the Compensation Committee
Measured against compensation peer group
Serves as the baseline from which short-term incentives are calculated
|
|
|
Short-Term Incentives
Purpose: Provide formulaic incentives to achieve or exceed budgeted Adjusted Net Sales (1) and Adjusted Net Income (2) and drive non-financial initiatives supporting our success |
| |
Annual cash-based bonus plan expressed as a percentage of the NEO’s weighted average base salary
Incentive payouts range from threshold to maximum levels, depending on level of performance measured against Compensation Committee determined metrics
Bonus payment based on the achievement of two financial objectives – budgeted Adjusted Net Sales and Adjusted Net Income – eight non-financial objectives relating to: design, clinical, regulatory and commercialization projects; and, with the exception of Mr. McDonald, leadership
|
|
|
Long-Term Incentives
Purpose: Create alignment with shareholder interests; motivate, attract and retain top talent |
| |
Service-Based Awards:
Restricted Stock Units vest in equal or substantially equal amounts on each of the first four anniversaries of the grant date
Stock Appreciation Rights vest in equal or substantially equal amounts on each of the first four anniversaries of the grant date
Performance-Based Awards:
Relative Total Shareholder Return Performance Stock Units are subject to a three-year relative total shareholder return market condition
Adjusted Free Cash Flow Performance Stock Units are subject to achievement of a three-year cumulative adjusted free cash flow target
|
|
|
29
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
| | | |
U.S. Target Total
Cash Benchmark Percentile |
| |||
| Damien McDonald | | | | | 69th | | |
| Thad Huston | | | | | >75th | | |
| Keyna Skeffington | | | | | 51st | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
30
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
| | | |
2019 Base Salary
($) |
| |
2018 Base Salary
($) |
| |
Change from
2018(1) |
| |||||||||
| Damien McDonald | | | | | 933,202 | | | | | | 933,202 | | | | | | 0% | | |
| Thad Huston | | | | | 516,674 | | | | | | 492,754 | | | | | | 5% | | |
| Keyna Skeffington | | | | | 433,751 | | | | | | 395,479 | | | | | | 10% | | |
| Edward Andrle | | | | | 440,000 | | | | | | 400,000 | | | | | | 10% | | |
| Alistair Simpson | | | | | 433,751 | | | | | | 395,479 | | | | | | 10% | | |
| | | |
U.S. Target Total
Cash Benchmark Percentile |
| |||
| Damien McDonald | | | | | 69th | | |
| Thad Huston | | | | | >75th | | |
| Keyna Skeffington | | | | | 51st | | |
|
Name
|
| |
2019 STIP Minimum
(Percentage of Base Salary) |
| |
2019 STIP Target
(Percentage of Base Salary)(1) |
| |
2019 STIP Maximum
(Percentage of Target) |
| |||||||||
| Damien McDonald | | | | | 0% | | | | | | 125% | | | | | | 171% | | |
| Thad Huston | | | | | 0% | | | | | | 90% | | | | | | 160% | | |
| Keyna Skeffington | | | | | 0% | | | | | | 70% | | | | | | 160% | | |
| Edward Andrle | | | | | 0% | | | | | | 65% | | | | | | 156% | | |
| Alistair Simpson | | | | | 0% | | | | | | 60% | | | | | | 156% | | |
|
31
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
| | | |
Non-Financial Objectives
|
| |||||||||||||||||||||||||||
| | | |
Design
|
| |
Clinical
|
| |
Regulatory
|
| |
Commercialization
|
| |
Leadership
|
| |||||||||||||||
| Damien McDonald | | | | | 10% | | | | | | 10% | | | | | | 15% | | | | | | 5% | | | | | | N/A | | |
| Thad Huston | | | | | 10% | | | | | | 10% | | | | | | 15% | | | | | | 5% | | | | | | 15% | | |
| Keyna Skeffington | | | | | 10% | | | | | | 10% | | | | | | 15% | | | | | | 5% | | | | | | 15% | | |
| Edward Andrle | | | | | 10% | | | | | | 10% | | | | | | 15% | | | | | | 5% | | | | | | 20% | | |
| Alistair Simpson | | | | | 10% | | | | | | 10% | | | | | | 15% | | | | | | 5% | | | | | | 20% | | |
| | | |
STIP
Target (% of Base Salary)(1) |
| |
Financial
Performance Weight % |
| |
Weighted
Financial Performance Payout % |
| |
Leadership
Weight % |
| |
Leadership
Payout % |
| |
Weighted
Non- Financial Performance Payout % |
| |
STIP
Payout % |
| |
STIP
Payout ($)(2) |
| ||||||||||||||||||||||||
|
Damien McDonald
|
| | | | 125% | | | | | | 75% | | | | | | 0% | | | | | | NA | | | | | | N/A | | | | | | 25% | | | | | | 25% | | | | | | 277,245 | | |
| Thad Huston | | | | | 90% | | | | | | 60% | | | | | | 0% | | | | | | 15% | | | | | | 12% | | | | | | 25% | | | | | | 37% | | | | | | 170,088 | | |
| Keyna Skeffington | | | | | 70% | | | | | | 60% | | | | | | 0% | | | | | | 15% | | | | | | 12% | | | | | | 25% | | | | | | 37% | | | | | | 106,289 | | |
| Edward Andrle | | | | | 65% | | | | | | 55% | | | | | | 0% | | | | | | 20% | | | | | | 14% | | | | | | 25% | | | | | | 39% | | | | | | 107,116 | | |
| Alistair. Simpson | | | | | 60% | | | | | | 55% | | | | | | 7.34% | | | | | | 20% | | | | | | 14% | | | | | | 25% | | | | | | 46% | | | | | | 113,445 | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
32
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
| | | |
RSUs ($)
|
| |
SARs ($)
|
| |
rTSR PSUs ($)
|
| |
FCF PSUs ($)
|
| |
Total Award
Value ($) |
| |||||||||||||||
| Damien McDonald | | | | | 1,250,000 | | | | | | 1,250,000 | | | | | | 1,500,000 | | | | | | 1,500,000 | | | | | | 5,500,000 | | |
| Thad Huston | | | | | 500,000 | | | | | | 500,000 | | | | | | 500,000 | | | | | | 500,000 | | | | | | 2,000,000 | | |
| Keyna Skeffington | | | | | 225,000 | | | | | | 225,000 | | | | | | 225,000 | | | | | | 225,000 | | | | | | 900,000 | | |
| Edward Andrle | | | | | 187,500 | | | | | | 187,500 | | | | | | 187,500 | | | | | | 187,500 | | | | | | 750,000 | | |
| Alistair Simpson | | | | | 187,500 | | | | | | 187,500 | | | | | | 187,500 | | | | | | 187,500 | | | | | | 750,000 | | |
|
33
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
|
TSR Performance
Percentile Rank |
| |
Percent Funding for Objective
|
| |||
| ≥90th | | | | | 200% | | |
| 80th | | | | | 150% | | |
| 50th | | | | | 100% | | |
| 30th | | | | | 40% | | |
| <30th | | | | | 0% | | |
|
ABIOMED, Inc.
Baxter International Inc.
Becton, Dickinson and Company
Boston Scientific Corporation
Cantel Medical Corp.
CONMED Corporation
DexCom, Inc.
Edwards Lifesciences Corporation
Globus Medical, Inc.
Haemonetics Corporation
Hill-Rom Holdings, Inc.
Hologic, Inc.
Insulet Corporation
Integer Holdings Corporation
Integra LifeSciences Holdings Corp.
|
| |
Intuitive Surgical, Inc.
Invacare Corporation
Masimo Corporation
Medtronic plc
Natus Medical Incorporated
Nevro Corp.
Nuvasive, Inc.
ResMed Inc.
Smith & Nephew plc
Stryker Corporation
Teleflex Incorporated
Varian Medical Systems, Inc.
Wright Medical Group N.V.
Zimmer Biomet Holdings, Inc.
|
|
|
FCF Achievement
Relative to FCF Target(1) |
| |
Percent Funding for Objective
|
| |||
| ≥150% | | | | | 200% | | |
| 125% | | | | | 150% | | |
| 100% | | | | | 100% | | |
| 60% | | | | | 20% | | |
| <60% | | | | | 0% | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
34
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
| | | |
2020 Base Salary
($) |
| |
Increase
from 2019 |
| |
2020 STIP at
Target |
| |
Change from
2019 |
| ||||||||||||
| Damien McDonald | | | | | 979,862 | | | | | | 5% | | | | | | 125% | | | | | | – | | |
| Thad Huston | | | | | 532,174 | | | | | | 3% | | | | | | 90% | | | | | | – | | |
| Keyna Skeffington | | | | | 459,776 | | | | | | 6% | | | | | | 70% | | | | | | – | | |
|
35
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
| | | |
2020 STIP
Minimum (Percentage of Base Salary) |
| |
2020 STIP
Target (Percentage of Base Salary) |
| |
2020 STIP
Maximum (Percentage of Target) |
| |||||||||
| Damien McDonald | | | | | 0% | | | | | | 125% | | | | | | 171% | | |
| Thad Huston | | | | | 0% | | | | | | 90% | | | | | | 160% | | |
| Keyna Skeffington | | | | | 0% | | | | | | 70% | | | | | | 160% | | |
|
Percent Achievement of Sales
Objective |
| |
Percent Achievement of Income
Objective |
| |
Percent Funding for
Objective |
|
|
>110%
|
| |
>110%
|
| |
175%
|
|
|
110%
|
| |
110%
|
| |
175%
|
|
| | | |
Linear Interpolation: 1:7.50
|
| |||
|
100%
|
| |
100%
|
| |
100%
|
|
| | | |
Linear Interpolation: 1:16.67 (Sales)
1.50 (Income) |
| |||
|
97%
|
| |
90%
|
| |
50%
|
|
|
<97%
|
| |
<90%
|
| |
0%
|
|
| | | |
Design
|
| |
Clinical and
Regulatory |
| |
Commercialization
|
| |
Leadership
|
| ||||||||||||
| Damien McDonald | | | | | 10% | | | | | | 20% | | | | | | 10% | | | | | | NA | | |
| Thad Huston | | | | | 10% | | | | | | 20% | | | | | | 10% | | | | | | 15% | | |
| Keyna Skeffington | | | | | 10% | | | | | | 20% | | | | | | 10% | | | | | | 15% | | |
| | | |
RSUs ($)
|
| |
SARs ($)
|
| |
rTSR PSUs ($)
|
| |
FCF PSUs ($)
|
| ||||||||||||
| Damien McDonald | | | | | 1,500,000 | | | | | | 1,250,000 | | | | | | 1,500,000 | | | | | | 1,500,000 | | |
| Thad Huston | | | | | 500,000 | | | | | | 500,000 | | | | | | 500,000 | | | | | | 500,000 | | |
| Keyna Skeffington | | | | | 250,000 | | | | | | 250,000 | | | | | | 250,000 | | | | | | 250,000 | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
36
|
|
| Executive Compensation | |
| Compensation Discussion & Analysis | |
|
TSR Performance
Percentile Rank |
| |
Percent Funding
for Objective |
| |||
| ≥90th | | | | | 200% | | |
| 80th | | | | | 150% | | |
| 50th | | | | | 100% | | |
| 30th | | | | | 40% | | |
| <30th | | | | | 0% | | |
|
ABIOMED, Inc.
Baxter International Inc.
Becton, Dickinson and Company
Boston Scientific Corporation
Cantel Medical Corp.
CONMED Corporation
DexCom, Inc.
Edwards Lifesciences Corporation
Globus Medical, Inc.
Haemonetics Corporation
Hill-Rom Holdings, Inc.
Hologic, Inc.
Insulet Corporation
Integer Holdings Corporation
Integra LifeSciences Holdings Corp.
|
| |
Intuitive Surgical, Inc.
Invacare Corporation
Masimo Corporation
Medtronic plc
Natus Medical Incorporated
Nevro Corp.
NuVasive, Inc.
Penumbra Inc.
ResMed Inc.
Smith & Nephew plc
Stryker Corporation
Teleflex Incorporated
Varian Medical Systems, Inc.
Wright Medical Group N.V.
Zimmer Biomet Holdings, Inc.
|
|
|
37
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation Discussion & Analysis
|
|
|
FCF Achievement
Relative to FCF Target |
| |
Percent Funding
for Objective |
| |||
| ≥150% | | | | | 200% | | |
| 125% | | | | | 150% | | |
| 100% | | | | | 100% | | |
| 60% | | | | | 20% | | |
| <60% | | | | | 0% | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
38
|
|
| Executive Compensation | |
| Compensation of Executive Officers and Directors | |
|
Name and Principal Position
|
| |
Year
|
| |
Salary
($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(1)(3) |
| |
All Other
Compensation ($)(1)(4) |
| |
Total
($) |
| |||||||||||||||||||||
|
Damien McDonald
Chief Executive Officer |
| | | | 2019 | | | | | | 933,202 | | | | | | 4,309,277 | | | | | | 1,249,978 | | | | | | 277,244 | | | | | | 362,226 | | | | | | 7,131,927 | | |
| | | 2018 | | | | | | 951,218 | | | | | | 3,522,492 | | | | | | 1,124,847 | | | | | | 999,131 | | | | | | 514,940 | | | | | | 7,112,628 | | | |||
| | | 2017 | | | | | | 847,925 | | | | | | 2,350,821 | | | | | | – | | | | | | 848,095 | | | | | | 1,368,920 | | | | | | 5,415,761 | | | |||
|
Thad Huston
Chief Financial Officer |
| | | | 2019 | | | | | | 510,694 | | | | | | 1,519,670 | | | | | | 499,998 | | | | | | 170,088 | | | | | | 139,192 | | | | | | 2,839,642 | | |
| | | 2018 | | | | | | 511,458 | | | | | | 1,174,164 | | | | | | 374,940 | | | | | | 480,257 | | | | | | 431,233 | | | | | | 2,972,052 | | | |||
| | | 2017 | | | | | | 296,759 | | | | | | 3,158,878 | | | | | | – | | | | | | 269,641 | | | | | | 157,907 | | | | | | 3,883,185 | | | |||
|
Keyna Skeffington
Senior Vice President, General Counsel and Company Secretary |
| | | | 2019 | | | | | | 424,183 | | | | | | 683,719 | | | | | | 224,988 | | | | | | 106,289 | | | | | | 128,751 | | | | | | 1,567,930 | | |
| | | 2018 | | | | | | 410,166 | | | | | | 658,627 | | | | | | 162,473 | | | | | | 251,619 | | | | | | 134,393 | | | | | | 1,617,278 | | | |||
| | | 2017 | | | | | | 215,599 | | | | | | 274,962 | | | | | | 258,412 | | | | | | 118,407 | | | | | | 108,865 | | | | | | 976,245 | | | |||
|
Edward Andrle
General Manager, NM |
| | | | 2019 | | | | | | 429,231 | | | | | | 569,913 | | | | | | 187,479 | | | | | | 107,116 | | | | | | 81,202 | | | | | | 1,374,941 | | |
|
Alistair Simpson
General Manager, CS |
| | | | 2019 | | | | | | 424,183 | | | | | | 569,913 | | | | | | 187,479 | | | | | | 113,445 | | | | | | 153,660 | | | | | | 1,448,680 | | |
|
| | | |
Severance and
Termination Payments ($) |
| |
Supplemental
Health Insurance ($) |
| |
Housing
Allowance ($)(a) |
| |
Car
Allowance ($)(b) |
| |
Qualified
Supplemental Pension Payments ($)(c) |
| |
Non-Qualified
Deferred Compensation and Defined Contribution Plan Registrant Contributions ($)(d) |
| |
Cash in Lieu
of Pension ($)(e) |
| |
Other
($)(f) |
| |
Total
($) |
| |||||||||||||||||||||||||||
|
Damien McDonald
|
| | | | – | | | | | | 28,381 | | | | | | 122,471 | | | | | | 22,644 | | | | | | – | | | | | | – | | | | | | 162,643 | | | | | | 26,087 | | | | | | 362,226 | | |
|
Thad Huston
|
| | | | – | | | | | | 21,823 | | | | | | – | | | | | | 16,840 | | | | | | – | | | | | | – | | | | | | 89,360 | | | | | | 11,169 | | | | | | 139,192 | | |
|
Keyna Skeffington
|
| | | | – | | | | | | 34,628 | | | | | | – | | | | | | 16,840 | | | | | | – | | | | | | – | | | | | | 69,922 | | | | | | 7,361 | | | | | | 128,751 | | |
|
Edward Andrle
|
| | | | – | | | | | | 26,215 | | | | | | – | | | | | | – | | | | | | 11,200 | | | | | | 40,222 | | | | | | – | | | | | | 3,565 | | | | | | 81,202 | | |
|
Alistair Simpson
|
| | | | – | | | | | | 28,259 | | | | | | – | | | | | | 16,840 | | | | | | – | | | | | | – | | | | | | 70,865 | | | | | | 37,696 | | | | | | 153,660 | | |
|
39
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation of Executive Officers and Directors
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
40
|
|
| Executive Compensation | |
| Compensation of Executive Officers and Directors | |
| | | | | | | | | |
Estimated Future Payouts Under
Non-Equity Incentive Plan Awards |
| |
Estimated Future Payouts
Under Equity Incentive Plan: Performance Stock Units (PSUs) (#) |
| |
All Other
Stock Awards: Number of Shares of Service- Based RSUs (#) |
| |
All Other
Option Awards: Number of Securities Underlying SARs (#) |
| |
Exercise
or Base Price of SAR Awards ($/Sh) |
| |
Grant
Date Fair value of RSU and SAR Awards ($)(1)(2) |
| ||||||||||||||||||||||||||||||||||||||||||
|
Name
|
| |
Grant
Date |
| |
Threshold
($) |
| |
Target
($) |
| |
Maximum
($) |
| |
Threshold
($) |
| |
Target
($) |
| |
Maximum
($) |
| |||||||||||||||||||||||||||||||||||||||||||||
|
Damien McDonald
|
| | | | | | | | | | 0 | | | | | | 869,283 | | | | | | 1,486,474 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | – | | | | | | | | | | | | | | |
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 6,170 | | | | | | 15,424 | | | | | | 30,848 | | | | | | | | | | | | – | | | | |
|
(2)
|
| | | | | 1,559,339 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 3,085 | | | | | | 15,424 | | | | | | 30,848 | | | | | | | | | | | | | | | | |
|
(2)
|
| | | | | 1,499,984 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,853 | | | | | | | | | | |
|
(1)
|
| | | | | 1,249,954 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 39,357 | | | | | | 97.25(2) | | | | | | 1,249,978 | | | |||
|
Thad Huston
|
| | | | | | | | | | 0 | | | | | | 360,339 | | | | | | 576,542 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 2,056 | | | | | | 5,141 | | | | | | 10,282 | | | | | | | | | | | | – | | | | |
|
(2)
|
| | | | | 519,746 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 1,028 | | | | | | 5,141 | | | | | | 10,282 | | | | | | | | | | | | | | | | |
|
(2)
|
| | | | | 499,962 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,141 | | | | | | | | | | |
|
(1)
|
| | | | | 499,962 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,743 | | | | | | 97.25(2) | | | | | | 499,998 | | | |||
|
Keyna Skeffington
|
| | | | | | | | | | 0 | | | | | | 225,178 | | | | | | 360,285 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 925 | | | | | | 2,313 | | | | | | 4,626 | | | | | | | | | | | | – | | | | |
|
(2)
|
| | | | | 233,840 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 463 | | | | | | 2,313 | | | | | | 4,262 | | | | | | | | | | | | | | | | |
|
(2)
|
| | | | | 224,939 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,313 | | | | | | | | | | |
|
(1)
|
| | | | | 224,939 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,084 | | | | | | 97.25(2) | | | | | | 224,988 | | | |||
|
Edward Andrle
|
| | | | | | | | | | 0 | | | | | | 274,658 | | | | | | 428,466 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 771 | | | | | | 1,928 | | | | | | 3,856 | | | | | | | | | | | | – | | | | |
|
(2)
|
| | | | | 194,917 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 386 | | | | | | 1,928 | | | | | | 3,856 | | | | | | | | | | | | | | | | |
|
(2)
|
| | | | | 187,498 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928 | | | | | | | | | | |
|
(1)
|
| | | | | 187,498 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,903 | | | | | | 97.25(2) | | | | | | 187,479 | | | |||
|
Alistair Simpson
|
| | | | | | | | | | 0 | | | | | | 191,918 | | | | | | 299,392 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 771 | | | | | | 1,928 | | | | | | 3,856 | | | | | | | | | | | | – | | | | |
|
(2)
|
| | | | | 194,917 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | 386 | | | | | | 1,928 | | | | | | 3,856 | | | | | | | | | | | | | | | | |
|
(2)
|
| | | | | 187,498 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928 | | | | | | | | | | |
|
(1)
|
| | | | | 187,498 | | | |||
| | | 03/30/2019 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,903 | | | | | | 97.25(2) | | | | | | 187,479 | | | |||
|
|
41
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation of Executive Officers and Directors
|
|
| | | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
|
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(1) |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable(2) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#)(3) |
| |
Market Value
of Shares or Units of Stock That Have Not Vested ($)(4) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested |
| ||||||||||||||||||||||||
|
Damien McDonald
|
| | | | 87,114 | | | | | | 43,556 | | | | | | 44.79 | | | | | | 11/4/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 10,378 | | | | | | 31,134 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | – | | | | | | 39,357 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 16,744 (5) | | | | | | 1,263,000 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 26,704(6) | | | | | | 2,014,283 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 8,901(7) | | | | | | 671,402 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 9,546(8) | | | | | | 720,055 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 12,853 (9) | | | | | | 969,502 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,729 (10) | | | | | | 960,148 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,729(11) | | | | | | 960,148 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,424(12) | | | | | | 1,163,432 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,424(13) | | | | | | 1,163,432 | | | |||
|
Thad Huston
|
| | | | 3,460 | | | | | | 10,377 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | – | | | | | | 15,743 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 3,189(14) | | | | | | 240,546 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 9,567 (15) | | | | | | 721,639 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 19,813(16) | | | | | | 1,494,495 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 3,182 (8) | | | | | | 240,018 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 5,141(9) | | | | | | 387,786 | | | | | | – | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,243 (10) | | | | | | 320,049 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,243(11) | | | | | | 320,049 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,141(12) | | | | | | 387,786 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,141(13) | | | | | | 387,786 | | | |||
|
Keyna Skeffington
|
| | | | 7,602 | | | | | | 7,601 | | | | | | 59.97 | | | | | | 6/12/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1,499 | | | | | | 4,497 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | – | | | | | | 7,084 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 2,292(17) | | | | | | 172,886 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,378(8) | | | | | | 103,943 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 901(18) | | | | | | 67,962 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 2,313(9) | | | | | | 174,470 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,838 (10) | | | | | | 138,640 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,838(11) | | | | | | 138,640 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,313(12) | | | | | | 174,470 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,313(13) | | | | | | 174,470 | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
42
|
|
| Executive Compensation | |
| Compensation of Executive Officers and Directors | |
| | | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
|
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(1) |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable(2) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#)(3) |
| |
Market Value
of Shares or Units of Stock That Have Not Vested ($)(4) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested |
| ||||||||||||||||||||||||
|
Edward Andrle
|
| | | | 29,717 | | | | | | 0 | | | | | | 69.39 | | | | | | 10/19/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1,724 | | | | | | 5,169 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | – | | | | | | 5,903 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 10,416(19) | | | | | | 785,679 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,375(7) | | | | | | 103,716 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 4,127(6) | | | | | | 311,300 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,590(8) | | | | | | 119,934 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928(9) | | | | | | 145,429 | | | | | | – | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,121(10) | | | | | | 159,987 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,121(11) | | | | | | 159,987 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928(12) | | | | | | 145,429 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928(13) | | | | | | 145,429 | | | |||
|
Alistair Simpson
|
| | | | 1,724 | | | | | | 5,169 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | – | | | | | | 5,903 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,208(7) | | | | | | 91,119 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 3,624(6) | | | | | | 273,358 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,590(8) | | | | | | 119,934 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928(9) | | | | | | 145,429 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,121 (10) | | | | | | 159,987 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,121(11) | | | | | | 159,987 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928(12) | | | | | | 145,429 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,928(13) | | | | | | 145,429 | | | |||
|
|
43
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation of Executive Officers and Directors
|
|
| | | |
Stock Options
|
| |
Stock Shares
|
| ||||||||||||||||||
|
Name
|
| |
Number of LivaNova
Option Shares Acquired on Exercise (#) |
| |
Value Realized
on Exercise ($) |
| |
Number of LivaNova
Shares Acquired on Vesting (#) |
| |
Value Realized
on Vesting ($) |
| ||||||||||||
| Damien McDonald | | | | | | | | | | | | | | | | | 37,731 | | | | | | 3,109,651 | | |
| Thad Huston | | | | | | | | | | | | | | | | | 17,346 | | | | | | 1,382,921 | | |
| Keyna Skeffington | | | | | | | | | | | | | | | | | 1,907 | | | | | | 152,963 | | |
| Edward Andrle | | | | | 29,718 | | | | | | 156,614 | | | | | | 9,621 | | | | | | 902,900 | | |
| Alistair Simpson | | | | | | | | | | | | | | | | | 2,947 | | | | | | 270,040 | | |
|
Name
|
| |
Executive
Contributions in Last Fiscal Year ($) |
| |
Registrant
Contributions in Last Fiscal Year ($)(1) |
| |
Aggregate
Earnings in Last Fiscal Year ($) |
| |
Aggregate
Withdrawals/ Distributions in Last Fiscal Year ($) |
| |
Aggregate
Balance at Last Fiscal Year ($) |
| |||||||||||||||
| Edward Andrle | | | | | – | | | | | | 40,222 | | | | | | 30,254 | | | | | | – | | | | | | 169,015 | | |
|
Plan category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights (#) |
| |
Weighted-
average exercise price of outstanding options, warrants and rights ($) |
| |
Number of
securities remaining available for future issuance under equity compensation plans (#) |
| |||||||||
| Equity compensation plans approved by security holders | | | | | | | | | | | | | | | | | | | |
|
LivaNova PLC 2015 Incentive Award Plan and Sub-Plan(1)
|
| | | | 2,788,448 | | | | | | 77.06 | | | | | | 4,903,894 | | |
|
Cyberonics Legacy Plans(2)
|
| | | | 235,844 | | | | | | 52.10 | | | | | | 1,855,720 | | |
| Equity compensation plans not approved by security holders | | | | | | | | | | | | | | | | | | | |
|
Cyberonics, Inc. New Employee Equity Inducement Plan(4)
|
| | | | | | | | | | | | | | | | 290,185 | | |
|
Total
|
| | | | 3,024,292 | | | | | | 64.58 | | | | | | 7,049,799 | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
44
|
|
| Executive Compensation | |
| Compensation of Executive Officers and Directors | |
|
Type of Payment
or Benefit |
| |
Termination
without Cause(1) |
| |
Separation due to
Change in Control(2) |
| |
Separation due to
Disability(3) |
| |
Separation due to
Death(4) |
| |
Separation due to
Retirement |
| |||||||||||||||
| Severance | | | | $ | 933,202 | | | | | | – | | | | | | – | | | | | $ | 3,732,809 | | | | | | – | | |
| STIP | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| LTIP | | | | | – | | | | | $ | 6,972,797 | | | | | $ | 1,334,556 | | | | | $ | 1,334,556 | | | | | | – | | |
| Benefits | | | | $ | 333,845 | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Total | | | | $ | 1,267,047 | | | | | $ | 6,972,797 | | | | | $ | 1,334,556 | | | | | $ | 5,067,365 | | | | | | – | | |
|
45
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation of Executive Officers and Directors
|
|
|
Type of Payment
or Benefit |
| |
Termination
Without Cause(1) |
| |
Separation due to
Change in Control(2) |
| |
Separation due to
Disability |
| |
Separation due to
Death(3) |
| |
Separation due to
Retirement |
| |||||||||||||||
| Severance | | | | $ | 516,674 | | | | | | – | | | | | | – | | | | | $ | 2,066,696 | | | | | | – | | |
| STIP | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| LTIP | | | | | – | | | | | $ | 3,084,484 | | | | | | – | | | | | | – | | | | | | – | | |
| Benefits | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Total | | | | $ | 516,674 | | | | | $ | 3,084,484 | | | | | | – | | | | | $ | 2,066,696 | | | | | | – | | |
|
Type of Payment
or Benefit |
| |
Termination
without Cause(1) |
| |
Separation due to
Change in Control(2) |
| |
Separation due to
Disability(3) |
| |
Separation due to
Death(4) |
| |
Separation due to
Retirement |
| |||||||||||||||
| Severance | | | | $ | 433,751 | | | | | | – | | | | | | – | | | | | $ | 1,735,004 | | | | | | – | | |
| STIP | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
46
|
|
| Executive Compensation | |
| Compensation of Executive Officers and Directors | |
|
Type of Payment
or Benefit |
| |
Termination
without Cause(1) |
| |
Separation due to
Change in Control(2) |
| |
Separation due to
Disability(3) |
| |
Separation due to
Death(4) |
| |
Separation due to
Retirement |
| |||||||||||||||
| LTIP(1) | | | | | – | | | | | $ | 695,535 | | | | | | – | | | | | $ | 176,275 | | | | | | – | | |
| Benefits | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Total | | | | $ | 433,751 | | | | | $ | 695,535 | | | | | | – | | | | | $ | 1,911,279 | | | | | | – | | |
|
Type of Payment
or Benefit |
| |
Termination
without Cause ($)(1) |
| |
Separation due to
Change in Control(2) |
| |
Separation due to
Disability |
| |
Separation due to
Death(3) |
| |
Separation due to
Retirement |
| |||||||||||||||
| Severance | | | | $ | 440,000 | | | | | | – | | | | | | – | | | | | $ | 500,000 | | | | | | – | | |
| STIP | | | | $ | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| LTIP | | | | $ | – | | | | | $ | 1,466,057 | | | | | | – | | | | | | – | | | | | | – | | |
| Benefits | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Total | | | | | 440,000 | | | | | $ | 1,466,057 | | | | | | – | | | | | $ | 500,000 | | | | | | – | | |
|
47
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Executive Compensation
|
|
|
Compensation of Executive Officers and Directors
|
|
|
Type of Payment
or Benefit |
| |
Termination
without Cause ($)(1) |
| |
Separation due to
Change in Control(2) |
| |
Separation due to
Disability(3) |
| |
Separation due to
Death(4) |
| |
Separation due to
Retirement |
| |||||||||||||||
| Severance | | | | $ | 433,751 | | | | | | – | | | | | | – | | | | | $ | 1,735,004 | | | | | | – | | |
| STIP | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| LTIP(1) | | | | | – | | | | | $ | 850,122 | | | | | $ | 220,281 | | | | | $ | 220,281 | | | | | | – | | |
| Benefits | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Total | | | | $ | 433,751 | | | | | $ | 850,122 | | | | | $ | 220,281 | | | | | $ | 1,955,285 | | | | | | – | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
48
|
|
| Executive Compensation | |
| Compensation of Executive Officers and Directors | |
|
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Stock
Awards ($)(1) |
| |
Total ($)
|
| |||||||||
| Francesco Bianchi | | | | | 133,000 | | | | | | 109,890 | | | | | | 242,890 | | |
| William Kozy | | | | | 116,000 | | | | | | 109,890 | | | | | | 225,890 | | |
| Daniel Moore | | | | | 185,000 | | | | | | 184,908 | | | | | | 369,908 | | |
| Hugh Morrison | | | | | 146,000 | | | | | | 109,890 | | | | | | 255,890 | | |
| Alfred Novak | | | | | 133,000 | | | | | | 109,890 | | | | | | 242,890 | | |
| Sharon O’Kane | | | | | 125,000 | | | | | | 109,890 | | | | | | 234,890 | | |
| Arthur Rosenthal | | | | | 130,000 | | | | | | 109,890 | | | | | | 239,890 | | |
| Andrea Saia | | | | | 125,000 | | | | | | 109,890 | | | | | | 234,890 | | |
| Stacy Enxing Seng(2) | | | | | 62,890 | | | | | | 109,890 | | | | | | 172,780 | | |
|
49
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
50
|
|
| AUDIT MATTERS | |
| Audit and Compliance Committee Report | |
|
51
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
AUDIT MATTERS
|
|
|
Fees Paid to PricewaterhouseCoopers
|
|
| | | |
Year Ended
December 31, 2019 |
| |
Year Ended
December 31, 2018 |
| ||||||
| | | |
(in thousands)
|
| |||||||||
| Audit Fees(1) | | | | $ | 7,510 | | | | | $ | 8,274 | | |
| Audit-Related Fees(2) | | | | | – | | | | | $ | 18 | | |
| Tax Fees(3) | | | | $ | 443 | | | | | $ | 387 | | |
| All Other Fees(4) | | | | | 1 | | | | | $ | 1 | | |
| Total | | | | $ | 7,954 | | | | | $ | 8,680 | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
52
|
|
| AUDIT MATTERS | |
| Pre-Approval Policies and Procedures | |
|
53
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
54
|
|
|
55
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Proposal No. 4 Ordinary Resolution to Grant Authority to Allot Shares for a Period of Five Years
|
|
|
Board Recommendation
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
56
|
|
|
57
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Subject
|
| |
Existing Articles
|
| |
Proposed Change
|
|
| Election of Directors | | |
Directors of the Company are elected by a plurality of votes cast.
|
| |
Directors of the Company shall be elected by the affirmative vote of the majority of votes cast at an annual meeting of shareholders in uncontested elections. A plurality vote standard will continue to apply to contested director elections.
|
|
| Untraced Members | | |
Among other requirements, before the Company can sell the shares of an untraced member, it must publish an advertisement in a leading national daily newspaper published in the United Kingdom and in a newspaper circulating in the area of the registered address or last known address of such member.
|
| |
Among other requirements, before the Company can sell the shares of an untraced member, the Company must make reasonable and appropriate tracing inquiries and send a notice to such member’s last known address.
|
|
| Quorum at an Adjourned Meeting | | |
One qualifying person present and entitled to vote.
|
| |
Members present in person or by proxy who together represent at least a majority of the voting rights, which is the same quorum required for an annual general meeting.
|
|
| Bonus Issues | | |
Board may only capitalise profits and certain other sums for the purpose of paying up shares to be issued under a bonus issue: (i) in ordinary shares to the holders of ordinary shares on an equal per share basis; (ii) for certain purposes in connection with awards made under the Company’s incentive plans; and (iii) otherwise with the approval of an ordinary resolution of shareholders.
|
| |
In addition, the Board will be permitted to capitalise profits and certain other sums for the purpose of paying up the nominal value of shares to be issued upon exercise of any warrant (or other right to subscribe) for shares in the Company. This may be used in connection with any equity or equity linked securities that may be issued in connection with the strategic capital raising options currently being evaluated by the Company (as described above).
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
58
|
|
| Proposal No. 6 Special Resolution to Adopt New Articles | |
| Board Recommendation | |
|
59
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
Share Ownership Information
|
|
|
|
|
| | | |
Amount and Nature of Beneficial Ownership(1)
|
| |||||||||||||||||||||
|
Name of Beneficial Owner
|
| |
Shares
Owned |
| |
Shares
Acquirable Within 60 Days |
| |
Total
Beneficial Ownership |
| |
Percent of
Class(2) |
| ||||||||||||
| Named Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | | | |
| Damien McDonald | | | | | 73,481 | | | | | | 4,451 | | | | | | 77,932 | | | | | | * | | |
| Edward Andrle | | | | | 46,241 | | | | | | 688 | | | | | | 46,929 | | | | | | * | | |
| Thad Huston | | | | | 20,910 | | | | | | 11,502 | | | | | | 32,412 | | | | | | * | | |
| Alistair Simpson | | | | | 3,440 | | | | | | 604 | | | | | | 4,044 | | | | | | * | | |
| Keyna Skeffington | | | | | 2,216 | | | | | | 1,146 | | | | | | 3,362 | | | | | | * | | |
| Directors: | | | | | | | | | | | | | | | | | | | | | | | | | |
| Francesco Bianchi | | | | | 1,520 | | | | | | – | | | | | | 1,520 | | | | | | * | | |
| Stacy Enxing Seng | | | | | – | | | | | | – | | | | | | – | | | | | | * | | |
| William Kozy | | | | | 1,576 | | | | | | – | | | | | | 1,576 | | | | | | * | | |
| Daniel Moore(3) | | | | | 28,352 | | | | | | – | | | | | | 28,352 | | | | | | * | | |
| Hugh Morrison(4) | | | | | 1,520 | | | | | | – | | | | | | 1,520 | | | | | | * | | |
| Alfred Novak | | | | | 9,570 | | | | | | – | | | | | | 9,570 | | | | | | * | | |
| Sharon O’Kane, Ph.D. | | | | | 4,228 | | | | | | – | | | | | | 4,228 | | | | | | * | | |
| Arthur Rosenthal, Ph.D. | | | | | 18,615 | | | | | | – | | | | | | 18,615 | | | | | | * | | |
| Andrea Saia | | | | | 2,998 | | | | | | – | | | | | | 2,998 | | | | | | * | | |
|
All current executive officers and directors as a group (14 persons)
|
| | | | 214,667 | | | | | | 18,391 | | | | | | 233,058 | | | | | | * | | |
| 5% Holders:(5) | | | | | | | | | | | | | | | | | | | | | | | | | |
|
BlackRock, Inc.(6)
New York, NY 10055 55 East 52nd Street |
| | | | 5,954,330 | | | | | | – | | | | | | 5,954,330 | | | | | | 12.05% | | |
|
Franklin Resources, Inc.(7)
One Franklin Parkway San Mateo, CA 94403-1906 |
| | | | 3,348,444 | | | | | | – | | | | | | 3,348,444 | | | | | | 6.78% | | |
|
T. Rowe Price Associates, Inc.(8)
100 E. Pratt Street Baltimore, MD 21202 |
| | | | 2,766,521 | | | | | | – | | | | | | 2,766,521 | | | | | | 5.60% | | |
|
Harris Associates L.P.(9)
111. S. Wacker, Suite 4000 Chicago, IL 60606 |
| | | | 2,697,007 | | | | | | – | | | | | | 2,697,007 | | | | | | 5.46% | | |
|
PRIMECAP Management Company(10)
177 E. Colorado Blvd., 11th Floor Pasadena, CA 91105 |
| | | | 2,437,830 | | | | | | – | | | | | | 2,437,830 | | | | | | 5.02% | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
60
|
|
| Share Ownership Information | |
| Delinquent Section 16(a) Reports | |
|
61
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
62
|
|
|
63
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
64
|
|
|
65
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
66
|
|
| GENERAL MATTERS | |
| Frequently Asked Questions About the AGM | |
|
67
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
GENERAL MATTERS
|
|
|
Frequently Asked Questions About the AGM
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
68
|
|
| GENERAL MATTERS | |
| Frequently Asked Questions About the AGM | |
|
69
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
GENERAL MATTERS
|
|
|
Frequently Asked Questions About the AGM
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
70
|
|
| GENERAL MATTERS | |
| Frequently Asked Questions About the AGM | |
|
71
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
GENERAL MATTERS
|
|
|
Other Business
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
72
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-i
|
|
Clause
|
| |
Page
|
| |||
44. NOTICES AND OTHER COMMUNICATIONS | | | | | A-36 | | |
45. DESTRUCTION OF DOCUMENTS | | | | | A-38 | | |
46. WINDING UP | | | | | A-39 | | |
47. INDEMNITY AND INSURANCE | | | | | A-39 | | |
48. DISPUTE RESOLUTION | | | | | A-39 | | |
|
A-ii
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-1
|
|
|
|
|
|
|
|
|
A-2
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-3
|
|
|
|
|
|
|
|
|
A-4
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-5
|
|
|
|
|
|
|
|
|
A-6
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-7
|
|
|
|
|
|
|
|
|
A-8
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-9
|
|
|
|
|
|
|
|
|
A-10
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-11
|
|
|
|
|
|
|
|
|
A-12
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-13
|
|
|
|
|
|
|
|
|
A-14
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-15
|
|
|
|
|
|
|
|
|
A-16
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-17
|
|
|
|
|
|
|
|
|
A-18
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-19
|
|
|
|
|
|
|
|
|
A-20
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-21
|
|
|
|
|
|
|
|
|
A-22
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-23
|
|
|
|
|
|
|
|
|
A-24
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-25
|
|
|
|
|
|
|
|
|
A-26
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-27
|
|
|
|
|
|
|
|
|
A-28
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-29
|
|
|
|
|
|
|
|
|
A-30
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-31
|
|
|
|
|
|
|
|
|
A-32
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-33
|
|
|
|
|
|
|
|
|
A-34
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-35
|
|
|
|
|
|
|
|
|
A-36
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-37
|
|
|
|
|
|
|
|
|
A-38
|
| |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
www.livanova.com
|
| | | |
|
|
|
|
|
|
| | | |
|
| |
LIVANOVA | 2020 Proxy Statement
|
| |
|
| |
A-39
|
|